Cyclacel Pharmaceuticals Announces That Brian Schwartz, M.D. Was Elected to Its Board of Directors
December 21 2020 - 07:00AM
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
"Cyclacel" or the "Company"), a biopharmaceutical company
developing innovative medicines based on cancer cell biology, today
announced the election of Brian Schwartz, M.D., to its Board
of Directors.
"We are very pleased to have Brian join the Board of Directors
of Cyclacel. His extensive clinical and product development
experience further adds to the strength of our Board and will
support management’s efforts to build shareholder value," said
Christopher Henney, Ph.D., Chairman of the Board of Cyclacel.
“Brian’s experience in all development stages of innovative
medicines for cancer will be very valuable as we advance our
business strategy."
“I am excited to join the Board at an important moment in the
Company’s history,” said Dr. Schwartz. “After evaluating the
scientific and clinical merits of Cyclacel’s medicines, I am
enthusiastic of the prospects of fadraciclib and CYC140. These two
internally discovered molecules have competitive product profiles
and address oncology indications with large unmet medical needs.
The clinical development plans and Cyclacel’s experienced
management team provide a strong basis for success in the Company’s
programs.”
Dr. Schwartz has wide-ranging experience as a drug development
expert in pharmaceutical and biotechnology industries primarily in
oncology, hematology, and rare diseases. During the past decade he
has served as Senior Vice President, Head of Research &
Development and Chief Medical Officer of ArQule Inc., which
was acquired for $2.7bn by Merck & Co. in 2020. Prior to
ArQule, Dr. Schwartz was CMO at Ziopharm, having previously held
several senior leadership roles at Bayer and LEO Pharma. He is
currently a Board Member of LifeSci Acquisition Corp, Mereo
Biopharma and Enlivex. In addition, he serves as an advisor, SAB
member and independent consultant for numerous biotech and
investment companies.
He received his medical degree from the University of Pretoria,
South Africa, completed a fellowship at the University of Toronto,
Canada and practiced medicine prior to his career in the
biopharmaceutical industry.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical
company developing innovative cancer medicines based on cell cycle,
transcriptional regulation and mitosis biology. The transcriptional
regulation program is evaluating fadraciclib, a CDK2/9 inhibitor,
in solid tumors and hematological malignancies. The anti-mitotic
program is evaluating CYC140, a PLK1 inhibitor, in advanced
cancers. Cyclacel's strategy is to build a diversified
biopharmaceutical business based on a pipeline of novel drug
candidates addressing oncology and hematology indications. For
additional information, please visit www.cyclacel.com.
Forward-looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended
utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory
filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to
differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later
clinical trials, trials may have difficulty enrolling, Cyclacel may
not obtain approval to market its product candidates, the risks
associated with reliance on outside financing to meet capital
requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
Company faces, please refer to our most recent Annual Report on
Form 10-K and other periodic and other filings we file with the
Securities and Exchange Commission and are available at
www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts
Company: Paul McBarron, (908)
517-7330, pmcbarron@cyclacel.comInvestor Relations: Russo
Partners LLC, Jason Assad, (646) 218-4604,
jason.assad@russopartnersllc.com
© Copyright 2020 Cyclacel Pharmaceuticals, Inc. All Rights
Reserved. The Cyclacel logo and Cyclacel® are trademarks of
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Mar 2023 to Mar 2024